COPD and PE: A clinical dilemma by Moua, Teng & Wood, Kenneth
© 2008 Dove Medical Press Limited.   All rights reserved
International Journal of COPD 2008:3(2) 277–284 277
REVIEW
COPD and PE:   A clinical dilemma
Teng Moua1
Kenneth Wood2
1Department of Internal Medicine, 
2Section of Pulmonary and Critical 
Care Medicine, University of 
Wisconsin Hospitals and Clinics, 
Madison, WI, USA
Correspondence: Kenneth E Wood
University of Wisconsin Hospitals 
and Clinics, Section of Pulmonary and 
Critical Care Medicine, 600 Highland Ave, 
Madison, WI 53792–9988, USA
Tel + 1 608 261 1299
Fax +1 608 263 3104
Email kew@medicine.wisc.edu
Abstract: Dyspnea in patients with known chronic obstructive pulmonary disease (COPD) can 
be a clinical challenge due to the nonspeciﬁ  c nature of atypical presentations. Typical features 
of fever, productive cough, and wheezing on presentation support COPD exacerbation, while 
absence of such ﬁ  ndings may warrant further evaluation for underlying etiologies, including 
pulmonary embolism (PE). It is suspected that one in four patients with atypical COPD exacerba-
tion may have PE as an underlying or concomitant cause of acute dyspnea. This review discusses 
the clinical presentation of COPD and PE, and presents an overview of the rationale for pursuing 
work-up for thromboembolic disease in the setting of known obstructive lung diseases.
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Introduction
The chronic obstructive pulmonary disease (COPD) patient presenting with acute dys-
pnea can be a diagnostic challenge in both the outpatient and inpatient arenas. Many 
cardiopulmonary diseases, including acute pulmonary embolism (PE), are worsened 
or masked by the presence of COPD. While diagnostic tests such as B-type natriuretic 
peptide have led to differentiating dyspnea in heart failure from COPD exacerbation, 
there are no proven clinical criteria to help delineate acute pulmonary embolism from 
COPD. This is attributable to the overlap and nonspeciﬁ  city of clinical features com-
mon to both diseases.
Guidelines presented by the World Health Organization (WHO) and Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) for the diagnosis of COPD 
stress the chronicity of dyspnea with exposure to relevant risk factors (GOLD et al 
2005). Further diagnostic evaluation includes pulmonary function testing that reveals 
obstruction and supportive ﬁ  ndings on chest X-ray (CXR). Acute exacerbation is 
diagnosed by clinical means and presents with a worsening of dyspnea with or 
without sputum change, a decline in exercise tolerance, and exam ﬁ  ndings of air 
trapping and poor lung aeration. The progression usually takes a few days and does 
not present acutely although the patient may be in respiratory distress at the time 
of evaluation.
The presentation of pulmonary embolism is similarly subtle with nonspeciﬁ  c 
clinical features such as acute dyspnea, tachycardia, and pleuritic chest pain. While 
COPD remains a clinical diagnosis, PE requires objective conﬁ  rmation of clot by an 
imaging study to warrant appropriate anticoagulation therapy. When recognizing that 
the mortality of untreated PE may be as high as 25%, it is crucial to incorporate PE 
into the differential diagnosis of a COPD exacerbation, and instructive to review the 
incidence of PE in COPD patients in the reported literature.
Prevalence and risk of PE with COPD
Thromboembolism represents a spectrum of disease, ranging from deep venous 
thrombosis (DVT) to PE and infarct. The incidence of DVT is 160 per 100,000 per-
sons, with 44% developing either symptomatic or asymptomatic PE (Kummer 1998). International Journal of COPD 2008:3(2) 278
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The estimated annual incidence of pulmonary embolism 
is 23–69 cases per 100,000 persons with hospitalizations 
resulting in 676,700 inpatient days (Kozak et al 2005). 
Approximately 187,000 new cases occur each year in 
individuals older than 45, half of which are considered 
idiopathic (Cushman et al 2004). A compilation of studies 
examining the incidence of DVT in patients with COPD 
reported a rate of 10%–12%, with the majority discov-
ered by surveillance studies and clinically asymptomatic 
(Prescott et al 1981; Erelel et al 2002; Ambrosetti et al 
2003). Autopsy studies have reported the incidence of 
PE in patients with COPD to be 28%–51% without deﬁ  n-
ing the percentage of suspected antemortem diagnoses 
(Prescott et al 1981). Retrospective work by Mispelaere 
and colleagues (2002) reported a 20% prevalence of PE in 
50 patients presenting with COPD exacerbation of nonin-
fectious etiology and a prospective study of 31 patients by 
the same investigators found a prevalence of 29% (9 of 31 
patients). Tillie-Leblond and colleagues (2006) similarly 
reported PE in 25% of patients presenting with noninfec-
tious COPD exacerbation. Using the Geneva score, three 
clinical features were statistically associated with PE; 1) 
prior history of malignancy, 2) history of DVT or PE, and 
3) drop in PaCO2 greater than 5 mmHg. Lower extremity 
Doppler studies conﬁ  rmed DVT in 51% of patients (Tillie-
Leblond et al 2006). However, Rutschmann and colleagues 
(2007) found only 4 cases of computed tomography (CT) 
proven PE out of 123 consecutive patients presenting with 
COPD exacerbation, representing a prevalence of 3.3%. 
As further studies are pursued, it is likely the prevalence of 
COPD-associated PE will become more apparent, making 
it important to include thromboembolism in the differential 
for COPD patients presenting with acute dyspnea.
The prevalence of PE in patients with COPD is important 
because of combined morbidity and mortality. In a follow-
up of 1487 patients from the Prospective Investigation of 
Pulmonary Embolism Diagnosis (PIOPED) study, Carson 
and colleagues (1996) found an adjusted estimated rela-
tive risk of death at one year with COPD and PE of 1.94, 
compared with 1.1 for patients with PE alone. The one year 
mortality of those with COPD and PE was 53.3%, in contrast 
to 15% of those with PE alone (Carson et al 1996).
The clinical evaluation
The clinical difﬁ  culty of diagnosing PE in the setting of 
COPD was described by Sharma and Sasahara (1975). Non-
speciﬁ  c ﬁ  ndings such as pleuritic pain, tachypnea, tachycar-
dia, and fever were common presentations of the two diseases 
(Sharma and Sasahara 1975). It is valuable to review the 
presenting features of each to appreciate their overlap.
Physical exam
In 1819, Laennec recorded the ﬁ  rst clinical descriptions of 
COPD as dyspnea, hyperresonant chest wall, diminished 
breath sounds, and wheezing. Contemporarily, classic exam 
ﬁ  ndings of barrel chest with hyperinﬂ  ated lungs, pursed 
lip breathing and accessory muscle use continue to signify 
airway obstruction. McGee (2001) reported 3 ﬁ  ndings that 
strongly support the diagnosis of COPD exacerbation: early 
inspiratory crackles, absence of cardiac dullness on percus-
sion, and decreased breath sounds. Absence of cardiac dull-
ness over the left lower sternal border had a sensitivity of 
15%, but speciﬁ  city of 99%, while unforced wheeze was only 
13%–56% sensitive and 86%–99% speciﬁ  c. Other clinical 
features of COPD exacerbation include productive cough 
secondary to an inciting respiratory infection, decreased 
exercise tolerance, and a breath – sound score of less than 9 
(a scoring system of listening to over 6 locations on the chest 
wall, and then rating and totaling breath sounds at each site 
from 0 [absent] to 4 [louder than normal]). McGee (2001) 
suggested clinically combining a historical picture of 70 or 
more pack-years of smoking, prior diagnosis of COPD, and 
decreased breath sounds to gain a likelihood ratio of 25.7 for 
active COPD exacerbation.
Stein’s evaluation of patients presenting with acute PE 
found dyspnea and tachypnea in 73% of patients, tachycardia 
in 30%, and pleuritic pain in 66% (Stein et al 1991). Rales 
were heard in approximately half of patients. More speciﬁ  c 
ﬁ  ndings in PE include hemoptysis, elevated neck veins, a 
loud P2 component of S2, and asymmetry in size of the 
lower extremities or calf tenderness. Of patients diagnosed 
with PE, only 45% had a presentation of pleuritic chest pain 
and hemoptysis (Pineda et al 2001). Other investigators 
noted only a history of cancer, asymmetric lower extremity 
swelling, or tachycardia as being reliable in arguing for a PE 
diagnosis, while a heart rate of less than 90 argued against 
it (McGee 2001). The reliability of lower extremity edema 
or asymmetry with calf pain (Homan’s sign) concerning for 
DVT has fallen out of favor in recent years due to nonspeci-
ﬁ  city of the ﬁ  nding.
A review of the clinical features of each disease suggests 
appreciable overlap making differentiation difﬁ  cult. For 
example, rales were prevalent in 58% of patients with PE 
while inspiratory crackles were 25%–77% sensitive and 98% 
speciﬁ  c in COPD (McGee 2001). Lesser et al found rales 
in 81% of patients with COPD and PE compared to 53% in International Journal of COPD 2008:3(2) 279
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COPD alone (Lesser et al 1992). Other overlapping features 
of COPD and PE on exam include tachypnea, tachycardia, 
and fever. Cough productive of sputum is less common 
in acute PE and more indicative of COPD exacerbation 
(Tillie-Leblond et al 2006; McGee 2001; Pineda et al 2001). 
Consequently, sub-acute PE may be overshadowed by or 
confound a bona ﬁ  de COPD exacerbation, escaping suspicion 
for diagnosis on physical exam.
Chest X-ray
Findings supportive of COPD on CXR include increased 
lung volumes and hyperinﬂ  ation. The presence of diffusely 
diminished lung markings suggests obliteration of supportive 
bronchial structures and correlates well with COPD; how-
ever, the CXR is otherwise nonspeciﬁ  c.
Stein’s evaluation of chest radiographs in 117 patients 
diagnosed with PE and no prior lung disease found 68% had 
nonspeciﬁ  c parenchymal abnormalities. The majority of ﬁ  nd-
ings were atelectasis and small pleural effusions (Stein et al 
1991). Classic features of PE on CXR, such as Westermark’s 
sign or Hampton’s hump, had poor sensitivity in the setting 
of COPD (Sharma and Sasahara 1975).
The CXR is of value for the evaluation of other acute 
causes of dyspnea including pneumonia, pleural effusion, 
pulmonary edema, or pneumothorax. The acutely dyspneic 
patient with minimal parenchymal ﬁ  ndings points towards 
vascular or bronchial etiologies such as asthma, COPD 
exacerbation, or thromboembolic disease.
Arterial blood gas
Arterial blood gas ﬁ  ndings in COPD are nonspeciﬁ  c, but are 
characterized by hypoxemia and hypercapnea, with elevated 
bicarbonate indicative of chronic metabolic correction of 
respiratory acidosis. In the acute setting, hypercapnea may be 
increased secondary to worsened deadspace ventilation and 
ventilation/perfusion (V/Q) mismatch caused by increased 
mucus production, bronchial constriction, or worsened alveo-
lar-capillary interface destruction with disease progression.
With pulmonary embolism, Stein and colleagues (1991) 
found the PaO2 to be less than 80 mmHg in 74% of patients 
without underlying pulmonary disease. The A–a gradient was 
greater than 20 mmHg in 76% of patients (Stein et al 1991). 
PaCO2 was commonly lower due to tachypnea, except in the 
presence of increased deadspace ventilation. In a case report 
of 3 patients with known COPD complicated by PE, Lipmann 
and Fein (1981) suggested a drop in PaCO2 of 10mmHg or 
more in otherwise previously hypercapneic COPD patients 
as indicative of thromboembolism. The mean increase in 
A–a gradient was 20 (±13) mmHg with poor response to 
conventional bronchodilator therapy (Lippmann and Fein 
1981). Tillie-Leblond and colleagues (2006) supported 
the ﬁ  ndings of Lipmann and Fein with a drop in PaCO2 of 
5 mmHg or more as statistically indicative of concomitant PE 
(Tillie-Leblond et al 2006). On the other hand, Lesser and col-
leagues (1992) reported 108 patients presenting with a history 
of COPD and newly diagnosed PE to have no difference in the 
A–a gradient or reduction in PaCO2, despite prior hypercapnea 
on arterial blood gas (Lesser et al 1992). Hypoxemia remained 
a shared blood gas ﬁ  nding nonspeciﬁ  c to either disease. The 
correction of hypoxemia with oxygen or positive pressure ﬂ  ow 
may support the diagnosis of COPD, while major pulmonary 
embolism with intrapulmonary or intracardiac shunt may be 
resistant to correction (Pineda et al 2001).
D-dimer
In conjunction with pretest probability, the D-dimer is the 
preferred diagnostic tool in the outpatient setting and emer-
gency department for DVT and PE. A low pretest probability 
and negative D-dimer effectively excludes thromboembolic 
disease. Work by Hartmann and colleagues (2000) found 
similar distribution of D-dimer results in 313 patients with 
and without COPD, suggesting COPD had no inﬂ  uence on 
the diagnostic accuracy of the test for thromboembolic dis-
ease. This also suggested there was no increased prevalence 
of elevated D-dimer with COPD exacerbation. Sohn and 
colleagues (2006) found the combination of a low pretest 
probability and negative D-dimer among subsets of patients 
with increased age, prior malignancy, heart failure, or COPD 
sufﬁ  cient in ruling out PE in 98% of all-comers. Missed 
diagnoses were most prevalent among subsets of patients 
with known malignancy (Sohn et al 2006). A systematic 
review found a negative D-dimer to be as diagnostically 
useful as a normal lung perfusion scan or negative duplex 
ultrasonography in the setting of low pretest probability 
(Stein et al 2004).
B-type natriuretic peptide
B-type natriuretic peptide may be elevated in any disorder, 
causing right ventricular dilatation including acute PE, 
COPD, pulmonary hypertension with corpulmonale, or 
left-to-right shunting, causing ventricular overload. Such 
elevations are usually smaller than those appreciated in left 
ventricular heart failure and negligible or absent in uncom-
plicated COPD exacerbation (Bando et al 1999).
In the setting of PE, brain natriuretic peptide (BNP) 
has served more as a prognostic tool relating severity of International Journal of COPD 2008:3(2) 280
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right ventricular dysfunction to outcome than a diagnostic 
measure of PE presence. Kucher and colleagues (2003) found 
increased morbidity and mortality with elevated BNP and PE 
in patients without history of heart disease. Those needing 
urgent triage to more acute settings or dying shortly after 
their presentation had higher overall BNP levels (Kucher et al 
2003). Kruger and colleagues (2004) studied 50 consecutive 
patients presenting with conﬁ  rmed PE and found those with-
out right ventricular dysfunction to have signiﬁ  cantly lower 
BNP levels. A cutoff greater than 90 pg/ml was associated 
with a risk ratio of 28.4 for right ventricular dysfunction, 
though BNP was not predictive of mortality or in-hospital 
complication in this particular study (Kruger et al 2004).
Troponin
With uncomplicated COPD, troponin values are negative 
and helpful in ruling out acute cardiac ischemia as a cause 
of respiratory decompensation. Very rarely is there myocyte 
damage, except with severe respiratory failure and related 
poor oxygenation and ischemia.
With PE, right ventricular dilatation increases wall tension 
and decreases endocardial perfusion promoting myocardial 
damage. Giannitsis and colleagues (2000) reported the pres-
ence of troponin values greater than 0.l ng/ml as indicative of 
right ventricular dysfunction associated with higher morbid-
ity and mortality. Meyer and colleagues (2000) proposed that 
nearly a third of patients presenting with clinically diagnosed 
pulmonary embolism have elevated troponoin – I values. This 
was signiﬁ  cantly associated with right ventricular dilatation 
and dysfunction as seen on echocardiography (Meyer et al 
2000). Elevated troponin is absent in the setting of uncom-
plicated COPD, but if present, an evaluation for underlying 
PE is appropriate, especially when there is absence of signs 
and symptoms of acute ischemia.
Lower extremity doppler 
ultrasonography
The majority of pulmonary emboli (87%–97%) originate 
from the lower extremities, particularly the deep veins of 
the thigh. A study by Winter and colleagues (1983) of 29 
patients with COPD exacerbation found 13 with DVT, two of 
which were later found to have PE postmortem (Winter et al 
1983). Of these patients, none presented with clinical signs 
of DVT. Erelel and colleagues (2002) followed 56 patients 
with hospitalized COPD and detected DVT by ultrasound 
in eight. Five were subsequently diagnosed with pulmonary 
embolism by high probability V/Q scanning (Erelel et al 
2002). Ambrosetti and colleagues (2003) suggested 10% 
of patients with COPD have concomitant DVT, though this 
number may far underestimate actual prevalence. The risk of 
DVT appears increased due to poor mobility with worsening 
respiratory status, chronic steroid use, and active smoking 
(Erelel et al 2002). Treatment guidelines for inpatient COPD 
exacerbations currently recommend the standard use of DVT 
prophylaxis (GOLD et al 2005).
V/Q scan
V/Q scanning remains the imaging study of choice for 
diagnosing PE in patients who cannot tolerate a dye load 
because of acute or chronic kidney disease. Unfortunately, 
intrinsic lung processes such as pulmonary edema, pneumo-
nia or anatomical perfusion, and ventilation defects confound 
the presence of thromboembolism. Lesser and colleagues 
(1992) found 60% of scans in the setting of COPD were of 
intermediate probability, with 22% later diagnosed with PE 
by angiography. High probability scans were positive for 
PE (5 of 5) while low probability scans did not have simi-
lar negative predictive values as compared with a general 
population because of increased pretest probability (Lesser 
et al 1992). Hartmann and colleagues (2000) concluded in 
a study of 509 patients with and without COPD that PE 
prevalence was similar between the two groups when V/Q 
was nondiagnostic and required angiographic conﬁ  rmation. 
An increased frequency of high and low probability scans 
were found compared with Lesser’s study. The utility of V/Q 
scanning in COPD appears diminished by a trend towards 
intermediate probability readings.
Spiral CT/angiography
Spiral chest CT and conventional angiography, the gold 
standards for PE diagnosis, were found by Hartmann and 
colleagues (2000) to have the same diagnostic performance in 
patients with and without COPD. Prevalence of PE appeared 
similar to other patient populations, suggesting equivalent 
sensitivity of the test and absence of association between 
PE and COPD.
Summary and recommendations
In studies evaluating PE and COPD, the presence of PE may 
be one in four among patients presenting with COPD exac-
erbation, a rate similar to a diagnosis of one in ﬁ  ve among 
all patients presenting with acute dyspnea and a high pretest 
probability (Hoellerich and Wigton 1986; Wells et al 1998; 
Mispelaere et al 2002; Tillie-Leblond et al 2006). A careful 
evaluation of the epidemiology of both diseases ﬁ  nds the 
prevalence of PE in COPD similar to that of other disease International Journal of COPD 2008:3(2) 281
COPD and PE
population groups, and increased combined morbidity and 
mortality is similar to that of COPD and heart failure, or 
COPD and myocardial infarction (Incalzi et al 1997; Groe-
newegan et al 2003; Lee et al 2003; Holguin et al 2005; 
Huiart et al 2005; Sin et al 2006). Lesser and Hartmann’s 
work conﬁ  rmed that PE does not appear to favor COPD 
(Lesser et al 1992; Hartmann et al 2000). Nonetheless, 
morbidity and mortality is increased at one year and while 
diagnosis is difﬁ  cult, an appreciation of the known morbidity 
of untreated thromboembolic disease makes acute detection 
of PE in the setting of COPD exacerbation important for 
improving clinical outcomes.
Findings of PE prevalence in COPD are also helpful in 
the clinical setting when attempting to make evidence-based 
decisions for diagnosis and management. The current litera-
ture suggests a one in four prevalence of PE in patients with 
atypical COPD exacerbation (Mispelaere et al 2002; Tillie-
Leblond et al 2006). Twenty percent prevalence translates 
to at least 20% pretest probability in this patient group, 
which can be in addition to probabilities obtained by other 
clinical decision criteria, such as Wells or the Geneva score. 
The presumptive prevalence of PE in all COPD patients 
with infectious features is approximately 3% as found by 
Rutschmann and colleagues (2007) while DVT prevalence 
is estimated at 10% among all COPD patients according to 
Ambrosetti and colleagues (2003). Since DVT and PE are on 
the same spectrum of thromboembolic disease, accounting 
for DVT will increase the pretest probability of thromboem-
bolic disease in those presenting with atypical exacerbations 
to a baseline of 30%, and those with typical features to 13%. 
Likelihood ratios for speciﬁ  c diagnostic tests can now be 
applied to obtain posttest probabilities for diagnosis of PE. 
As an example, Hartmann and colleagues (2000) found that 
V/Q perfusion scanning in patients with COPD yielded a 79% 
speciﬁ  city and 92% sensitivity when the test was interpreted 
as high probability, translating to a positive likelihood ratio 
of 4.38 {sensitivity/(1 – speciﬁ  city)}. Patients with atypical 
COPD exacerbation whom underwent V/Q perfusion scan-
ning would have a posttest probability of 65%, while those 
with typical exacerbations would yield a posttest probability 
of 40%, doubling in both cases our initial pretest probability, 
but not enough to rule in a positive diagnosis. This conﬁ  rms 
again the ﬁ  nding that perfusion scanning, even when inter-
preted as high probability for PE in the setting of COPD 
exacerbation, is a poor diagnostic choice in either patient 
population when clinical suspicion is low.
In review, very little on physical exam delineates COPD 
and PE in patients with acute respiratory distress. Findings 
suggestive of underlying thromboembolic disease include 
dyspnea, absence of fever or sputum change, and tachycar-
dia. Historical features such as prior DVT or PE, malignancy 
or decreased mobility are helpful and contributory to pre-
test probability. Hypoxemia is notable and nondiagnostic, 
with rales and wheezes overlapping both diseases. While 
suspicion of PE in patients presenting with noninfectious 
COPD exacerbation is intuitive, further cohort studies look-
ing directly at the presence of PE in patients with typical 
infectious features are needed to reveal further underlying 
prevalence.
Laboratory and imaging studies in conjunction with clini-
cal features contribute to pretest probability for PE. Though 
the presence of mildly elevated troponin and BNP in the 
setting of typical COPD exacerbation may provide clues 
as to underlying embolic disease, these values may be con-
founded by right or left ventricular failure and acute ischemia, 
all possible sequelae of advanced obstructive lung disease. 
Appropriate echocardiography and serial troponins to rule out 
ischemia would be warranted. Echocardiography may help 
delineate right vs. left ventricular dysfunction and diastolic 
failure contributing to an elevated BNP. The arterial blood 
gas is nonspeciﬁ  c and improved hypercapnea or hypoxemia 
with treatment is helpful in supporting uncomplicated COPD. 
A decrease in PaCO2 on initial presentation in the setting of 
prior hypercapnea with known COPD has been advocated 
as an indicator of underlying thromboembolism (Lippmann 
and Fein 1981; Tillie-Leblond et al 2006). It appears that 
patients with COPD develop DVT at rates similar to patients 
in a medical intensive care unit (Pomper and Luchman 1991; 
Kummer 1998; Ambrosetti et al 2003). Knowing this, and the 
fact that D-dimer distribution is similar in patients with and 
without COPD, makes it a useful test in conjunction with low 
pretest probability for ruling out thromboembolism. While 
management does not differ in sub-massive PE and DVT, 
PE remains more difﬁ  cult to diagnose, and obtaining lower 
extremity Doppler ultrasound may clinch thromboembolic 
diagnosis faster than more extensive studies. V/Q scans are 
the default imaging study in the setting of acute or chronic 
kidney disease, but are diminished by increased frequency of 
nondiagnostic intermediate probability ﬁ  ndings with COPD. 
Spiral CT has delineated similar prevalence of PE in patients 
with and without COPD, suggesting equivalent sensitivity 
of the test in both populations.
Figure 1 suggests a diagnostic algorithm for respiratory 
decompensation in patients with known COPD. The approach 
utilizes clinical prediction criteria for PE, such as the Wells 
criteria or Geneva score, to obtain a pretest probability and International Journal of COPD 2008:3(2) 282
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Figure 1 Respiratory decompensation in patients with established COPD.
Abbreviations: COPD, chronic obstructive pulmonary disease; PE, pulmonary embolism; V/Q, ventilation/perfusion ratio.
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combines this with features of COPD exacerbation. Clinical 
history, physical exam, and laboratory data provide the 
impetus for pursuing PE diagnosis. In the absence of typi-
cal symptoms such as productive cough, fever, or decreased 
breath sounds diffusely, obtaining laboratory and diagnos-
tic studies such as D-dimer, B – type natriuretic peptide, 
troponin, and arterial blood gas may be helpful in deﬁ  ning 
other underlying pathologies. Similarly, a nonresponse to 
aggressive COPD treatment with beta agonists, antibiotics, 
and steroids in patients with typical presentations supports 
evaluation for other causes of dyspnea.
Suspicion for PE in the setting of atypical COPD exacer-
bation can be divided into low, intermediate, or high pretest 
probabilities. Obtaining appropriate imaging beginning with 
assessment of serum creatinine is recommended as a ﬁ  rst 
step. Where creatinine is less than 1.5 mg/dl and suspicion is 
intermediate or high, direct evaluation by spiral CT or angiog-
raphy is the preferred conﬁ  rmatory test. If there is low pretest 
probability, direct evaluation by spiral CT or angiography 
may not be appropriate, particularly if acute or chronic kidney 
disease precludes possibly nephrotoxic dye load. In this set-
ting, lower extremity Doppler ultrasound and V/Q scanning 
may be helpful in establishing or ruling out diagnosis without 
risk of kidney injury. A low pre – test probability with a low 
D-dimer effectively rules out thromboembolism. Following 
the algorithm, high or intermediate pre – test probability and 
negative perfusion scanning or lower extremity Dopplers still 
warrants spiral CT or angiography. Often times, particularly 
in the setting of severe or advanced clinical picture, it may 
be necessary to forgo the possibility of false negative tests to 
obtain more deﬁ  nitive diagnostic imaging, so that treatment 
may be started in a timely fashion. Protecting the kidneys as 
much as possible from contrast nephropathy with standard 
pharmacological regimens is recommended.
Again, there is little general data evaluating the preva-
lence of PE in lone COPD with typical infectious features, 
making screening for PE on initial presentation unsupported. 
Rutschmann and colleagues (2007) argue against systematic 
screening in the setting of COPD exacerbation due to their 
ﬁ  ndings of low prevalence in all-comers. DVT prevalence 
though is suggested to be as high as 10% in all patients with 
COPD, and in conjunction with clinical suspicion, Doppler 
studies may be the appropriate ﬁ  rst imaging study to obtain 
if there is concern for thromboembolic diagnosis particularly 
if respiratory symptoms are equivocal.
In summary, patients with COPD exacerbation appear 
to experience sub-massive PE at rates similar to all patients 
presenting with dyspnea, as well as a high clinical suspicion 
for thromboembolism. Review of diagnostic laboratory and 
imaging studies as described above suggests an algorithm 
that incorporates appropriate pretest probability, laboratory 
studies such as D-dimer with emphasis on Doppler ultra-
sonography and CT angiography over perfusion scanning. 
Diagnosis of PE in COPD exacerbation is diminished by 
clinical difﬁ  culty, but incorporating thromboembolism into 
the differential may mean improved outcomes in COPD 
patients presenting with dyspnea and occult emboli.
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